NASDAQ:ECYT - Endocyte Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$23.9850 +0.02 (+0.08 %)
(As of 12/19/2018 10:18 AM ET)
Previous Close$23.97
Today's Range$23.98 - $23.99
52-Week Range$2.81 - $23.99
Volume166,158 shs
Average Volume1.93 million shs
Market Capitalization$1.97 billion
P/E Ratio-23.99
Dividend YieldN/A
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

Receive ECYT News and Ratings via Email

Sign-up to receive the latest news and ratings for ECYT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:ECYT
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio45.80
Quick Ratio45.80


Trailing P/E Ratio-23.99
Forward P/E Ratio-37.48
P/E GrowthN/A

Sales & Book Value

Annual Sales$70,000.00
Price / Sales28,127.55
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.99 per share
Price / Book12.05


EPS (Most Recent Fiscal Year)($1.00)
Net Income$-55,060,000.00
Net Margins-32,296.09%
Return on Equity-21.19%
Return on Assets-20.55%


Outstanding Shares82,090,000
Market Cap$1.97 billion

Endocyte (NASDAQ:ECYT) Frequently Asked Questions

What is Endocyte's stock symbol?

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

How were Endocyte's earnings last quarter?

Endocyte, Inc. (NASDAQ:ECYT) posted its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.01. The biopharmaceutical company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.02 million. Endocyte had a negative return on equity of 21.19% and a negative net margin of 32,296.09%. View Endocyte's Earnings History.

When is Endocyte's next earnings date?

Endocyte is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Endocyte.

What price target have analysts set for ECYT?

4 brokers have issued twelve-month price targets for Endocyte's stock. Their forecasts range from $21.00 to $21.00. On average, they anticipate Endocyte's stock price to reach $21.00 in the next year. This suggests that the stock has a possible downside of 12.4%. View Analyst Price Targets for Endocyte.

What is the consensus analysts' recommendation for Endocyte?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endocyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Endocyte.

Has Endocyte been receiving favorable news coverage?

News articles about ECYT stock have trended positive on Wednesday, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Endocyte earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days.

Who are some of Endocyte's key competitors?

Who are Endocyte's key executives?

Endocyte's management team includes the folowing people:
  • Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)
  • Mr. Michael T. Andriole, Chief Financial Officer (Age 45)
  • Dr. Alison A. Armour, Chief Medical Officer (Age 54)
  • Dr. Christopher P. Leamon, VP of R&D (Age 52)
  • Dr. Philip S. Low, Co-Founder, Chief Science Officer & Director (Age 70)

Who are Endocyte's major shareholders?

Endocyte's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.50%), VHCP Management II LLC (5.13%), Vanguard Group Inc. (4.29%), Vanguard Group Inc (4.29%), Baker BROS. Advisors LP (3.10%) and Perceptive Advisors LLC (2.97%). Company insiders that own Endocyte stock include Alison A Armour, Beth Taylor, Christopher P Leamon, Katherine Parker, Michael A Sherman, Michael T Andriole and Philip S Low. View Institutional Ownership Trends for Endocyte.

Which institutional investors are selling Endocyte stock?

ECYT stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., VHCP Management II LLC, Virtus ETF Advisers LLC, AQR Capital Management LLC, TIAA CREF Investment Management LLC, Asymmetry Capital Management L.P., Baird Financial Group Inc. and Rhumbline Advisers. Company insiders that have sold Endocyte company stock in the last year include Alison A Armour, Beth Taylor, Christopher P Leamon, Katherine Parker, Michael A Sherman, Michael T Andriole and Philip S Low. View Insider Buying and Selling for Endocyte.

Which institutional investors are buying Endocyte stock?

ECYT stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Janus Henderson Group PLC, VHCP Management III LLC, Perceptive Advisors LLC, Vanguard Group Inc, Vanguard Group Inc., Teachers Advisors LLC and Baker BROS. Advisors LP. View Insider Buying and Selling for Endocyte.

How do I buy shares of Endocyte?

Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endocyte's stock price today?

One share of ECYT stock can currently be purchased for approximately $23.9850.

How big of a company is Endocyte?

Endocyte has a market capitalization of $1.97 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe.

What is Endocyte's official website?

The official website for Endocyte is

How can I contact Endocyte?

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.

MarketBeat Community Rating for Endocyte (NASDAQ ECYT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  303 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  535
MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe ECYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel